Department of Nutritional Sciences, Temerty Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada.
Department of Medicine, University of Padova, Padova, Italy.
JAMA Netw Open. 2023 Jan 3;6(1):e2247868. doi: 10.1001/jamanetworkopen.2022.47868.
Caffeine is detoxified by cytochrome P450 1A2 (CYP1A2), and genetic variation in CYP1A2 impacts the rate of caffeine clearance. Factors that may modify the association between coffee intake and kidney disease remain unclear.
To assess whether CYP1A2 genotype modifies the association between coffee intake and kidney dysfunction.
DESIGN, SETTING, AND PARTICIPANTS: The Hypertension and Ambulatory Recording Venetia Study (HARVEST) was a prospective cohort study of individuals with stage 1 hypertension in Italy; HARVEST began on April 1, 1990, and follow-up is ongoing. The current study used data from April 1, 1990, to June 30, 2006, with follow-up of approximately 10 years. Blood pressure and biochemical data were collected monthly during the first 3 months, then every 6 months thereafter. Data were analyzed from January 2019 to March 2019. Participants were screened and recruited from general practice clinics. The present study included 1180 untreated participants aged 18 to 45 years with stage 1 hypertension; those with nephropathy, diabetes, urinary tract infection, and cardiovascular disease were excluded.
Coffee intake and CYP1A2 genotype rs762551 were exposures analyzed over a median follow-up of 7.5 (IQR, 3.1-10.9) years.
Albuminuria (defined as an albumin level of ≥30 mg/24 h) and hyperfiltration (defined as an estimated glomerular filtration rate of ≥150 mL/min/1.73 m2) were the primary outcomes as indicators of kidney dysfunction.
Among 1180 participants, genotyping, lifestyle questionnaires, and urine analysis data were obtained from 604 individuals (438 [72.5%] male) with a mean (SD) age of 33.3 (8.5) years and a mean (SD) body mass index (calculated as weight in kilograms divided by height in meters squared) of 25.4 (3.4). A total of 158 participants (26.2%) consumed less than 1 cup of coffee per day, 379 (62.7%) consumed 1 to 3 cups per day, and 67 (11.1%) consumed more than 3 cups per day. Genotype frequencies for rs762551 (260 participants [43.1%] with genotype AA, 247 participants [40.8%] with genotype AC, and 97 participants [16.1%] with genotype CC) did not differ between coffee intake categories. The level of risk of developing albuminuria, hyperfiltration, and hypertension, assessed by Cox regression and survival analyses, was not associated with coffee intake in the entire group or among fast metabolizers. The risks of albuminuria (adjusted hazard ratio [aHR], 2.74; 95% CI, 1.63-4.62; P < .001), hyperfiltration (aHR, 2.11; 95% CI, 1.17-3.80; P = .01), and hypertension (aHR, 2.81; 95% CI, 1.51-5.23; P = .001) increased significantly among slow metabolizers who consumed more than 3 cups per day.
In this study, the risks of albuminuria, hyperfiltration, and hypertension increased with heavy coffee intake only among those with the AC and CC genotypes of CYP1A2 at rs762551 associated with slow caffeine metabolism, suggesting that caffeine may play a role in the development of kidney disease in susceptible individuals.
重要性:咖啡因通过细胞色素 P450 1A2(CYP1A2)解毒,CYP1A2 基因变异会影响咖啡因的清除率。影响咖啡摄入与肾脏疾病之间关联的因素仍不清楚。
目的:评估 CYP1A2 基因型是否会改变咖啡摄入量与肾功能障碍之间的关联。
设计、地点和参与者:高血压和动态记录威尼斯研究(HARVEST)是一项针对意大利 1 期高血压患者的前瞻性队列研究;HARVEST 于 1990 年 4 月 1 日开始,随访仍在继续。本研究使用了 1990 年 4 月 1 日至 2006 年 6 月 30 日的数据,随访时间约为 10 年。在最初的 3 个月中,每月收集一次血压和生化数据,此后每 6 个月收集一次。数据分析于 2019 年 1 月至 2019 年 3 月进行。参与者是从普通诊所筛选和招募的。本研究纳入了 1180 名年龄在 18 至 45 岁之间、患有 1 期高血压且无肾病、糖尿病、尿路感染和心血管疾病的未接受治疗的参与者。
暴露因素:咖啡摄入量和 CYP1A2 基因型 rs762551 是在中位随访 7.5(IQR,3.1-10.9)年后分析的暴露因素。
主要结局和测量:白蛋白尿(定义为白蛋白水平≥30 mg/24 h)和高滤过(定义为估计肾小球滤过率≥150 mL/min/1.73 m2)是肾功能障碍的主要结局指标。
结果:在 1180 名参与者中,有 604 名个体(438 [72.5%] 名男性)提供了基因分型、生活方式问卷和尿液分析数据,这些个体的平均(SD)年龄为 33.3(8.5)岁,平均(SD)体重指数(体重以千克为单位除以身高以米为单位的平方)为 25.4(3.4)。共有 158 名参与者(26.2%)每天饮用少于 1 杯咖啡,379 名参与者(62.7%)每天饮用 1 至 3 杯咖啡,67 名参与者(11.1%)每天饮用超过 3 杯咖啡。rs762551(260 名参与者[43.1%]为基因型 AA、247 名参与者[40.8%]为基因型 AC、97 名参与者[16.1%]为基因型 CC)的基因型频率在咖啡摄入量类别之间没有差异。通过 Cox 回归和生存分析评估的发生白蛋白尿、高滤过和高血压的风险与整个组或快速代谢者的咖啡摄入量无关。白蛋白尿(调整后的危险比 [aHR],2.74;95%CI,1.63-4.62;P <.001)、高滤过(aHR,2.11;95%CI,1.17-3.80;P =.01)和高血压(aHR,2.81;95%CI,1.51-5.23;P =.001)的风险在每天饮用超过 3 杯咖啡的慢速代谢者中显著增加。
结论和相关性:在这项研究中,只有在 rs762551 与 CYP1A2 相关的 AC 和 CC 基因型的个体中,每天饮用大量咖啡会增加白蛋白尿、高滤过和高血压的风险,这表明咖啡因可能在易感个体中发挥作用在肾脏疾病的发展中。